Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06652100 · ClinicalTrials.gov registry record
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
A clinical trial of Acute Kidney Injury, sponsored by BioPorto Diagnostics.
- Active
- Registry status
- 800
- Enrollment target
- 12
- Study locations
NCT06652100 is a study of Acute Kidney Injury that is active but no longer recruiting, run by BioPorto Diagnostics. The registered enrollment target is 800 participants, below the 2,320-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (66% lower). The trial reports 12 study locations across 12 states.
The verdict
NCT06652100, a study of Acute Kidney Injury, is active but no longer recruiting, sponsored by BioPorto Diagnostics.
- ACTIVE NOT RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST ProNephro AKI (NGAL)
Study Locations (12)
Alabama
- The University of Alabama - Birmingham
California
- UC Davis - Sacramento
Connecticut
- Yale University - New Haven
Illinois
- University of Chicago - Chicago
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
New Mexico
- University of New Mexico - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2026-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06652100
The ClinicalTrials.gov registry entry for NCT06652100 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,320-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (66% lower). The listed sponsor is BioPorto Diagnostics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which ProNephro AKI (NGAL) is the first listed.
NCT06652100 reports 12 study locations spanning 12 distinct geographic areas - top geographies include Alabama, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06652100 about?
NCT06652100 is a clinical study titled "Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults". The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
What is the current status of trial NCT06652100?
This trial is currently active not recruiting. The enrollment target is 800 participants. The study started on 2024-10-28. Estimated completion is 2026-01-31.
What conditions does trial NCT06652100 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT06652100?
The interventions under investigation include: ProNephro AKI (NGAL) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06652100?
This trial is sponsored by BioPorto Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06652100 being conducted?
This trial has 12 study locations across Alabama, California, Connecticut, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.